Bormioli Pharma, an international manufacturer of pharmaceutical packaging and medical devices, today announced a significant increase of 47% in its North American sales for 2023.
This notable growth is a result of the company's evolving infrastructure and expanded capacity, tailored to meet the demands of the North American pharmaceutical market, including an increased need for pharmaceutical glass vials.
Bormioli Pharma strengthened its strategic focus on the US market four years ago by establishing a new legal entity and a commercial branch in the US.
From then on, the company’s on-site commercial team has been expanded, an FDA-approved warehouse established and dedicated product offerings compatible with regional standards have been designed.
For North American customers, this translates into the availability of a reliable and flexible packaging partner that can streamline their purchasing processes while reducing supply chain complexity, shortening their time-to-market and supporting them in the development of high-value projects with local, qualified support.
The pharmaceutical glass vials market is projected to grow from $12.1bn in 2023 to $24.1bn by 2033, expanding at a 7.10% CAGR, driven by rising pharmaceutical product demands.
The US market is one of the major growth contributors, (with an expected CAGR of 8.0% in North America for 2023-20282) with a high demand for suppliers capable of providing turn-key packaging solutions that meet regional standards, such as the use of glass Type I expansion 33.
Bormioli Pharma recently signed a key contract with a US-based global leader in allergen immunotherapy for the supply of ready-to-use, vertically integrated packaging kits for two of its major manufacturing sites in the US.
The full packaging kits include aluminum seals, rubber stoppers, Type I moulded glass vials and Type I tubular glass expansion 33 vials.
“To best serve our North American customers, we've adapted our manufacturing processes to produce Type I Glass expansion 33 vials in our European facilities, ensuring robust production and backup. We are collaborating with a US- based sterilisation company to prepare ready-to-use packaging kits.” said Johann Depperschmidt, Bormioli Pharma’s Head of Sales, Americas.
